{"Signatur": "CH_PATG_001", "Spider": "CH_BPatG", "Datum": "2017-08-29", "PDF": {"Datei": "CH_BPatG/CH_PATG_001_O2015-012_2017-08-29.pdf", "URL": "https://www.bundespatentgericht.ch/fileadmin/entscheide/O2015_012_Urteil_2017-08-29.pdf", "Checksum": "2043fdbef6fc21d3bd5dda356cb69bfa"}, "Scrapedate": "2026-04-05", "Num": ["O2015_012"], "Kopfzeile": [{"Sprachen": ["de"], "Text": "Bundespatentgericht 29.08.2017 O2015_012"}, {"Sprachen": ["fr"], "Text": "Bundespatentgericht 29.08.2017 O2015_012"}, {"Sprachen": ["it"], "Text": "Bundespatentgericht 29.08.2017 O2015_012"}], "Meta": [{"Sprachen": ["de"], "Text": "Eidgenossenschaft Bundespatentgericht "}, {"Sprachen": ["fr"], "Text": "Conféderation Bundespatentgericht "}, {"Sprachen": ["it"], "Text": "Confederazione Bundespatentgericht "}], "Abstract": [{"Sprachen": ["de", "fr", "it"], "Text": "Gutheissung Nichtigkeitsklage; Nichtzulassung verspäteter Einschränkung | Erfinderische Tätigkeit, Fachmann, Fachrichtervotum, Feststellungsklage, Kosten: Parteientschädigung, Lugano Übereinkommen, Neuheit, Örtliche Zuständigkeit national, Sistierung auf Antrag der Parteien, Unzulässige Änderung (Art. 123(2) EPÜ)"}], "ScrapyJob": "446973/64/2135", "Zeit UTC": "05.04.2026 03:17:34", "Checksum": "4d0a177484cbfebda55371720bbcce45", "Chunktext": "Auszug aus dem Entscheid Bundespatentgericht 29.08.2017 O2015_012\nRegeste:\nGutheissung Nichtigkeitsklage; Nichtzulassung verspäteter Einschränkung | Erfinderische Tätigkeit, Fachmann, Fachrichtervotum, Feststellungsklage, Kosten: Parteientschädigung, Lugano Übereinkommen, Neuheit, Örtliche Zuständigkeit national, Sistierung auf Antrag der Parteien, Unzulässige Änderung (Art. 123(2) EPÜ)\n\n2. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration, wherein the formulation comprises fulvestrant,\n30% or less weight of a pharmaceutically acceptable alcohol\nper volume of formulation, at least 1% weight of a pharmaceuti-\ncally-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount\nof a ricinoleate vehicle so as to prepare a formulation which is\ncapable after injection of attaining a therapeutically significant\nblood plasma fulvestrant concentration for at least 2 weeks.\n3. The use as claimed in claim 1 or 2, wherein the blood plasma\nfulvestrant concentration attained is at least 2.5 ngml-1 for at\nleast 2 weeks.\n4. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration, wherein the pharmaceutical formulation comprises\nfulvestrant, 30% or less weight of a pharmaceuticallyacceptable alcohol per volume of formulation, at least 1%\nweight of a pharmaceutically-acceptable non-aqueous ester\nsolvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to\nprepare a formulation of at least 45 mgml-1 of fulvestrant.\nwith dependent claims 5 to 17 to remain unchanged and claims\n18. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration, wherein the pharmaceutical formulation comprises\nfulvestrant, 15-25% weight of a pharmaceutically-acceptable\nalcohol per volume of formulation, 10-25% weight of a pharma-\nceutically-acceptable non-aqueous ester solvent miscible in a\nricinoleate vehicle per volume of formulation and a sufficient\namount of a ricinoleate vehicle so as to prepare a formulation of\nat least 45 mgml-1 of fulvestrant.\n19. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration, wherein the pharmaceutical formulation comprises\nfulvestrant, 17-23% weight of a pharmaceutically-acceptable\nalcohol per volume of formulation, 12-18% weight of pharma-\nceutically-acceptable non-aqueous ester solvent miscible in a\nricinoleate vehicle per volume of formulation and a sufficient\n\nSeite 4\nO2015_012\n\namount of a ricinoleate vehicle so as to prepare a formulation of\nat least 45 mgml-1 of fulvestrant.\nwith dependent claims 20 to 22 to remain unchanged and claims\n23. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration, wherein the pharmaceutical formulation comprises\nfulvestrant, 15-25% weight of a pharmaceutically-acceptable\nalcohol per volume of formulation, 10-25% weight of benzylbenzoate in a ricinoleate vehicle per volume of formulation\nand a sufficient amount of a ricinoleate vehicle so as to prepare\na formulation of at least 45 mgml-1 of fulvestrant.\n24. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration, wherein the pharmaceutical formulation comprises\nfulvestrant, 17-23% weight of a pharmaceutically-acceptable\nalcohol per volume of formulation, 12-18% weight of benzylbenzoate in a ricinoleate vehicle per volume of formulation\nand a sufficient amount of a ricinoleate vehicle so as to prepare\na formulation of at least 45 mgml-1 of fulvestrant.\nwith dependent claims 25 to 31 to remain unchanged.\n3. Auxiliary to no. 2 above, the Patent is to be upheld with the following\nlimited claims:\n1. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration to human patients, wherein the formulation comprises fulvestrant dissolved in a ricinoleate vehicle, a pharmaceutically acceptable non-aqueous ester solvent, and a pharmaceutically acceptable alcohol, and wherein the formulation is\nadapted for attaining a therapeutically significant blood plasma\nfulvestrant concentration for at least 2 weeks.\n2. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration to human patients, wherein the formulation comprises fulvestrant in solution, 30% or less weight of a pharmaceutically acceptable alcohol per volume of formulation, at least\n1% weight of a pharmaceutically-acceptable non-aqueous ester\nsolvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to\n\nSeite 5\nO2015_012\n\n"}